Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Rs 3,500 crore jolt to...

    Rs 3,500 crore jolt to Singh brothers as Delhi High Court upholds the arbitral award

    Written by Ruby Khatun Khatun Published On 2018-01-31T17:41:39+05:30  |  Updated On 16 Aug 2021 4:12 PM IST
    Rs 3,500 crore jolt to Singh brothers as Delhi High Court upholds the arbitral award
    Delhi High Court upholds Daiichi's Rs 3,500-crore arbitral award against Singh brothers

    New Delhi: After a long legal battle, Daiichi Sankyo has finally achieved a victory against Singh brothers as the Delhi High Court has allowed the firm to collect over $500 million from former Ranbaxy promoters Malvinder and Shivinder Singh as part of the international arbitration award.


    Justice Jayant Nath however, while delivering the verdict in court dismissed the objections to the enforcement of the award by 15 of the respondents in the case saying that the award cannot be enforced against the Singhs' children reports ET.


    According to lawyers from both sides, this means that Daiichi is allowed to enforce the award granted by a Singapore arbitration tribunal in April 2016.


    In 2013, Daiichi Sankyo had filed a petition against Singh brothers in Singapore tribunal to enforce the arbitral award. Daiichi claimed that Malvinder Singh and Shivinder Singh cloaked important information while selling Ranbaxy to the company in 2008. The generic company in 2013 pleaded guilty in the U.S. to charges of distributing adulterated medicines and falsifying data.


    The firm eventually had to reach a $500-million settlement with the US Department of Justice over these allegations.


    In 2016, the Singapore arbitration tribunal had directed Singh brothers to pay Rs 2,562 crore in damages giving the verdict in favour of Daiichi which has now valued at Rs 3,500 crore after including interest and legal fees.


    Read also: Ex-Ranbaxy owners to pay Rs 2,600 Crores to Daiichi for concealing facts


    Daiichi had approached the Delhi high court to collect the dues in May 2016, but the Singh brothers had argued in the Delhi High Court that the arbitral award was not enforceable under the Indian law and separately challenged the award in the Court of Appeal of Singapore.

    Read also: Singapore arbitration award of Rs 2,562 crore holds no grounds in India: Ex Ranbaxy Owners
    Daiichi SankyoDelhi high courtinternational arbitration awardMalvinder SinghRanbaxyShivinder SinghSingapore arbitration tribunalSingh brothers
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok